Use of platelet and erythroid growth factors during induction chemotherapy for acute lymphoblastic leukaemia in a Jehovah's Witness

Nivedita Arora, Arjun Gupta, Hsiao C. Li, Navid Sadeghi

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

We present a 21-year-old woman diagnosed with Philadelphia (Ph) chromosome-like CD20 positive B-cell acute lymphoblastic leukaemia (ALL). She was a Jehovah's Witness (JW) and declined all blood product transfusion support. She was initiated on the CALGB 10403 chemotherapy protocol for her ALL. She received darbepoetin alfa and romiplostim as supportive therapies for her disease/chemotherapy-associated anaemia and thrombocytopaenia. A complete remission was achieved with negative minimal residual disease and she remains in remission 18 months after diagnosis. This case report describes the successful treatment of an adult JW with Ph-like CD20 +B cell ALL, in the absence of blood product transfusions, using growth factor support.

Original languageEnglish (US)
Article numbere226497
JournalBMJ case reports
Volume11
Issue number1
DOIs
StatePublished - Dec 1 2018

Fingerprint Dive into the research topics of 'Use of platelet and erythroid growth factors during induction chemotherapy for acute lymphoblastic leukaemia in a Jehovah's Witness'. Together they form a unique fingerprint.

  • Cite this